JB Chemicals & Pharmaceuticals Ltd has scheduled its 50th Annual General Meeting (AGM) on June 17, 2026, to be held via video conferencing. The meeting will focus on voting for dividend approval, director reappointment, and the adoption of FY26 audited financial statements.

Torrent Pharmaceuticals' Q4 FY26 results surpassed expectations, largely due to the consolidation of JB Pharma. However, financial advisor Nirmal Bang maintains a 'Hold' stance on the company, setting a target price of Rs 4,898, as they see minimal growth potential given the current market valuations.

Torrent Pharma announces that its merger with JB Chemicals is nearing completion, with a final decision anticipated following the June hearing, suggesting a likely conclusion within 1-2 months.

JB Chemicals completed a significant stock trade of INR 24.1 crore on the National Stock Exchange, with each share trading at INR 2,105. Approximately 114,640 shares were exchanged in this deal.

JB Chemicals and Pharmaceuticals has proposed a final dividend of Rs. 9.3 per share for the fiscal year 2025-26, subject to shareholder approval at the Annual General Meeting. If approved, the dividend will be distributed within a month following the meeting.

JB Chemicals reported a 33% drop in Q4 net profit compared to last year, with earnings dropping from ₹1.5 billion to ₹1.01 billion. Additionally, quarterly revenue slipped slightly to ₹9.04 billion from ₹9.5 billion.

Despite a 30.4% year-on-year drop in Q4 net profit and a 4.8% decline in revenue, JB Chemicals' shares still rose by 2.9%, closing at ₹2,215 on the BSE, potentially suggesting investor optimism about the company's future prospects despite current business challenges in revenue, EBITDA, and international operations.

JB Chemicals executed a significant block trade on the National Stock Exchange (NSE), valued at approximately INR 31.3 crore, with each share trading at around INR 2006.7.